Clinical trials: Healthy Volunteers, Aged
Healthy
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 409306
The primary objective of the current study is to investigate the safety and tolerability of BI 409306 in healthy young and elderly male and female volunteers following oral administration of repeated rising doses, given once…
- Trial name
- NCT01611311
- Testing
- BI 409306
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers
Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older - 55 to 65 Years. Covicompare-Janssen
In response to the COVID-19 pandemic, several vaccines (Pfizer, Moderna, Astrazeneca, Janssen) have been developed and are being administered to millions of people in France and billions around the world through massive…
- Trial name
- CoviCompare_J (NCT05037266)
- Testing
- COVID-19 Vaccine Janssen (Ad26.COV2-S)
- Where
- 10 sites in France
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Alzheimer Disease
Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers
The purpose of this study is to examine the safety, tolerability and pharmacokinetics of single and multiple doses of NNI-362 in healthy aged population.
- Trial name
- NCT04074837
- Testing
- NNI-362
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Neuronascent, Inc.
Alzheimer's Disease
A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's Disease
- Trial name
- NCT05804383
- Testing
- BMS-984923
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Allyx Therapeutics
Pandemic Influenza
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age
The present study, randomized, single-blind, dose-ranging, multicenter study, will evaluate immunogenicity, safety and tolerability of two doses of adjuvanted and not-adjuvanted new swine-origin influenza A/H1N1 virus monovalent…
- Trial name
- NCT00971542
- Testing
- Monovalent A/H1N1 influenza vaccine
- Where
- 5 sites in Belgium, Chile and 3 more
- Volunteers
- 778 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Healthy Volunteer, Dry Age-related Macular Degeneration
Pharmacokinetics and Pharmacodynamics Study of LBS-008 in Healthy Volunteers Aged 50-85
This is a Phase 1b, parallel single-dose study to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of Tinlarebant when administered as an oral dose to elderly healthy volunteers.
- Trial name
- NCT05667688
- Testing
- Tinlarebant (LBS-008)
- Where
- Australia
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- RBP4 Pty Ltd
Meningitis, Meningococcal
Safety Study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months
The purpose of this study is to evaluate safety of meningococcal ACYW135 polysaccharide conjugate vaccine in healthy volunteers aged above 3 Months
- Trial name
- NCT02878291
- Testing
- Meningococcal ACYW135 Polysaccharide Conjugate Vaccine
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Healthy Subjects
Study to Evaluate the Safety and Pharmacokinetics of ASP2151 in Healthy Non-elderly and Elderly Subjects
The objective of this study is to evaluate the safety and the pharmacokinetics of ASP2151 after multiple oral dosing of ASP2151 in healthy non-elderly male and elderly male Japanese subjects, and to compare the pharmacokinetics…
- Trial name
- NCT02796118
- Testing
- ASP2151
- Where
- Japan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Influenza B
Dose, Safety, and Pathogenicity of a New Influenza B Strain
This is an exploratory study of an influenza B challenge strain to determine the optimum infectious titer of challenge agent in healthy participants 18 to 55 years of age.
- Trial name
- NCT06254820
- Testing
- influenza B/Connecticut/1/21 virus part a dose arm 1, influenza B/Connecticut/1/21 virus part a dose arm 2, influenza B/Connecticut/1/21 virus part b dose 1
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hvivo
Meningococcal Vaccine
A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules
This study is designed to describe the short-term immunogenicity and safety of 2 doses of Neisseria meningitidis group A, B, C, W, and Y vaccine (MenABCWY) separated by either 12 or 36 months during adolescence, and…
- Trial name
- NCT04440176
- Testing
- MenABCWY, Saline
- Where
- 20 sites in United States
- Volunteers
- 309 people, healthy volunteers welcome
- Sponsor
- Pfizer
Meningococcal Disease
Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.
The purpose of the study was to assess the immunogenicity and safety of two doses of Novartis Meningococcal B Recombinant (rMenB+OMV NZ) vaccine administered one month apart (0, 1 month schedule) in Korean adolescents aged…
- Trial name
- NCT01973218
- Testing
- Meningococcal B Recombinant vaccine rMenB+OMV NZ, Meningococcal ACWY-CRM conjugate vaccine
- Where
- 7 sites in South Korea
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Respiratory Syncytial Virus (RSV), Influenza A(H5N1)
Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of vaccines encoding the RSV monovalent antigen or the Flu hemagglutinin subtype 5 (H5) antigen in healthy participants aged 18 to…
- Trial name
- NCT07516418
- Testing
- H5 Flu Investigational Medical Product (IMP) 1, H5 Flu IMP 2, H5 Flu IMP 3
- Where
- 6 sites in Australia
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Sanofi
Bacterial Meningitis
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in India
This study will evaluate the immunogenicity of a single injection of Novartis Meningococcal ACWY conjugate vaccine in healthy subjects from the age of 2 years and above in India.
- Trial name
- NCT01547715
- Testing
- Meningococcal ACWY conjugate vaccine
- Where
- 4 sites in India
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Novartis
Healthy Volunteers
Pharmacokinetic Study of ASP1517 With Kremezin®
The objective of this study is to evaluate the effect of Kremezin® on the pharmacokinetics of single dose of ASP1517 in healthy non-elderly adult male subjects when administered concomitantly or in a time separated manner.
- Trial name
- NCT02693613
- Testing
- ASP1517, Kremezin®
- Where
- Japan
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Influenza
Study of Parenterally Administrated Adjuvanted Seasonal Influenza Vaccine in Healthy Elderly Volunteers
The safety of parenterally administrated investigational vaccine (commercial influenza vaccine formulated with adjuvant Matrix M) in healthy adults (age 18-50) and healthy elderly (age 65-75), will be investigated in the study.
- Trial name
- NCT01444482
- Testing
- Matrix M, Seasonal influenza vaccine
- Where
- Hungary
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Isconova AB
Relatively Healthy Volunteers
Daily Intake of Multivitamin & Mineral Supplementation Effects on Biological Age of Relatively Healthy Middle-aged Individuals
Micronutrients, such as vitamins and minerals, are required to sustain fundamental physiological processes in individuals. As individuals age, the risk of having suboptimal levels of micronutrients increases due to several…
- Trial name
- CEDIRA (NCT06666660)
- Testing
- Multivitamin/Mineral supplements
- Where
- 2 sites in Singapore
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- National University of Singapore
Respiratory Syncytial Virus, Human Metapneumovirus
Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age and Older
Study VCA25397 is a Phase 2b, observer-blind, randomized, placebo-controlled, parallel, case-driven proof of concept study that will enroll approximately 8000 adults aged 60 years and older to assess the clinical efficacy…
- Conditions
- Respiratory Syncytial Virus, Human Metapneumovirus, Healthy Volunteers
- Trial name
- NCT07810010
- Testing
- Bivalent RSV+HMPV protein vaccine
- Where
- 21 sites in Australia, United Kingdom
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- Sanofi